ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
235.88
-0.22 (-0.09%)
At close: Apr 25, 2025, 4:00 PM
237.00
+1.12 (0.47%)
After-hours: Apr 25, 2025, 6:31 PM EDT
ResMed Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for ResMed stock have an average target of 259.4, with a low estimate of 180 and a high estimate of 290. The average target predicts an increase of 9.97% from the current stock price of 235.88.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ResMed stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 4 | 3 | 3 | 3 | 3 | 4 |
| Hold | 5 | 6 | 6 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $247 → $255 | Hold | Maintains | $247 → $255 | +8.11% | Apr 24, 2025 |
| UBS | UBS | Strong Buy Maintains $290 → $285 | Strong Buy | Maintains | $290 → $285 | +20.82% | Apr 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $286 → $290 | Buy | Maintains | $286 → $290 | +22.94% | Apr 24, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $260 → $248 | Hold | Maintains | $260 → $248 | +5.14% | Apr 24, 2025 |
| Keybanc | Keybanc | Buy Maintains $269 → $274 | Buy | Maintains | $269 → $274 | +16.16% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
5.16B
from 4.69B
Increased by 10.15%
Revenue Next Year
5.55B
from 5.16B
Increased by 7.50%
EPS This Year
9.53
from 6.92
Increased by 37.76%
EPS Next Year
10.45
from 9.53
Increased by 9.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.4B | 5.9B | 6.4B | ||
| Avg | 5.2B | 5.5B | 6.0B | ||
| Low | 5.0B | 5.3B | 5.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0% | 13.4% | 15.2% | ||
| Avg | 10.2% | 7.5% | 7.3% | ||
| Low | 6.1% | 3.0% | 1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.09 | 11.43 | 12.96 | ||
| Avg | 9.53 | 10.45 | 11.44 | ||
| Low | 9.10 | 9.70 | 10.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.8% | 19.9% | 23.9% | ||
| Avg | 37.8% | 9.7% | 9.5% | ||
| Low | 31.6% | 1.8% | 1.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.